{"AAAEX": {"short_name": "AllianzGI Health Sciences Fund ", "long_name": "AllianzGI Health Sciences Fund Class P", "currency": "USD", "summary": "The investment seeks long-term capital appreciation.\n The fund seeks to achieve its objective by normally investing at least 80% of its net assets (plus borrowings made for investment purposes) in health sciences-related companies. The portfolio manager considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences. The fund will invest primarily in common stocks and other equity securities.", "manager_name": "Peter  Pirsch", "manager_bio": "Mr. Pirsch, CFA, is a senior portfolio manager, a senior analyst and a director with Allianz Global Investors, which he joined in 2018. He has management and research responsibilities for the Health Care team. Mr. Pirsch has 19 years of investment-industry experience. He previously worked at Aptigon Capital, Visium Asset Management, Surveyor Capital, Fred Alger Management and C.R. Bard. Before that, Mr. Pirsch was an analyst at UBS Investment Bank and Wells Fargo. He has a B.A. in economics and international relations from Bucknell University and an M.B.A. from Duke University, Fuqua School of Business. Mr. Pirsch is a CFA charterholder", "category": "Health", "family": "Allianz Global Investors", "exchange": "NAS", "market": "us_market"}, "AHSAX": {"short_name": "Alger Health Sciences Fund Clas", "long_name": "Alger Health Sciences Fund Class A", "currency": "USD", "summary": "The investment seeks long-term capital appreciation.\n The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of companies of any market capitalization that are engaged in the health sciences sector. It can invest in foreign securities.", "manager_name": "Daniel C. Chung", "manager_bio": "Dan Chung, CFA is Chief Executive Officer, Chief Investment Officer and Portfolio Manager of several Alger strategies. Dan joined Alger in 1994 and has 25 years of investment experience. He was named Chief Investment Officer in September 2001, President in 2003, and CEO in 2006. Dan graduated from Stanford University with B.A. and B.S. degrees, with Distinction and Phi Beta Kappa, in 1984. He earned his J.D. magna cum laude from Harvard Law School in 1987, where he was an editor of the Harvard Law Review. After law school, he served as law clerk for the Honorable Justice Anthony M. Kennedy, United States Supreme Court. He joined Simpson Thacher & Bartlett LLP in New York City in 1989 and earned an L.L.M. from New York University. Dan is a CFA charterholder and a member of the CFA Institute. Throughout his tenure at Alger, Dan has made numerous TV appearances on Bloomberg, CNBC, and Fox Business. Dan has also been featured and quoted frequently in Barron\u00e2\u0080\u0099s, Citywire, Forbes, Investment News, Pensions & Investments, USA Today, and the Wall Street Journal.", "category": "Health", "family": "Alger", "exchange": "NAS", "market": "us_market"}, "AHSCX": {"short_name": "Alger Health Sciences Fund Clas", "long_name": "Alger Health Sciences Fund Class C", "currency": "USD", "summary": "The investment seeks long-term capital appreciation.\n The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of companies of any market capitalization that are engaged in the health sciences sector. It can invest in foreign securities.", "manager_name": "Daniel C. Chung", "manager_bio": "Dan Chung, CFA is Chief Executive Officer, Chief Investment Officer and Portfolio Manager of several Alger strategies. Dan joined Alger in 1994 and has 25 years of investment experience. He was named Chief Investment Officer in September 2001, President in 2003, and CEO in 2006. Dan graduated from Stanford University with B.A. and B.S. degrees, with Distinction and Phi Beta Kappa, in 1984. He earned his J.D. magna cum laude from Harvard Law School in 1987, where he was an editor of the Harvard Law Review. After law school, he served as law clerk for the Honorable Justice Anthony M. Kennedy, United States Supreme Court. He joined Simpson Thacher & Bartlett LLP in New York City in 1989 and earned an L.L.M. from New York University. Dan is a CFA charterholder and a member of the CFA Institute. Throughout his tenure at Alger, Dan has made numerous TV appearances on Bloomberg, CNBC, and Fox Business. Dan has also been featured and quoted frequently in Barron\u00e2\u0080\u0099s, Citywire, Forbes, Investment News, Pensions & Investments, USA Today, and the Wall Street Journal.", "category": "Health", "family": "Alger", "exchange": "NAS", "market": "us_market"}, "AHSZX": {"short_name": "Alger Health Sciences Fund Clas", "long_name": "Alger Health Sciences Fund Class Z", "currency": "USD", "summary": "The investment seeks long-term capital appreciation.\n The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of companies of any market capitalization that are engaged in the health sciences sector. It can invest in foreign securities.", "manager_name": "Daniel C. Chung", "manager_bio": "Dan Chung, CFA is Chief Executive Officer, Chief Investment Officer and Portfolio Manager of several Alger strategies. Dan joined Alger in 1994 and has 25 years of investment experience. He was named Chief Investment Officer in September 2001, President in 2003, and CEO in 2006. Dan graduated from Stanford University with B.A. and B.S. degrees, with Distinction and Phi Beta Kappa, in 1984. He earned his J.D. magna cum laude from Harvard Law School in 1987, where he was an editor of the Harvard Law Review. After law school, he served as law clerk for the Honorable Justice Anthony M. Kennedy, United States Supreme Court. He joined Simpson Thacher & Bartlett LLP in New York City in 1989 and earned an L.L.M. from New York University. Dan is a CFA charterholder and a member of the CFA Institute. Throughout his tenure at Alger, Dan has made numerous TV appearances on Bloomberg, CNBC, and Fox Business. Dan has also been featured and quoted frequently in Barron\u00e2\u0080\u0099s, Citywire, Forbes, Investment News, Pensions & Investments, USA Today, and the Wall Street Journal.", "category": "Health", "family": "Alger", "exchange": "NAS", "market": "us_market"}, "BHCFX": {"short_name": "Baron Health Care Fund Retail S", "long_name": "Baron Health Care Fund Retail Shares", "currency": "USD", "summary": "The investment seeks capital appreciation.\n Under normal circumstances, the fund invests at least 80% of its net assets in equity securities in the form of common stock of companies engaged in the research, development, production, sale, delivery or distribution of products and services related to the health care industry. The Adviser uses various criteria to determine whether an issuer is engaged in activities related to the health care industry. It is non-diversified.", "manager_name": "Neal  Kaufman", "manager_bio": "Mr. Kaufman has worked at BAMCO as an analyst since March of 2005. From 2001 to 2005, he worked at Credit Suisse First Boston as a vice president and managed a portfolio in the Equity Proprietary Trading group. From 1996 to 2001, Mr. Kaufman practiced corporate law in New York. He graduated cum laude from Yale College with a B.A. in History in 1993, from Columbia Law School with a J.D. in 1996 and from Columbia Business School with an Executive M.B.A. in 2002.", "category": "Health", "family": "Baron Capital Group", "exchange": "NAS", "market": "us_market"}, "BHCHX": {"short_name": "Baron Health Care Fund Institut", "long_name": "Baron Health Care Fund Institutional Shares", "currency": "USD", "summary": "The investment seeks capital appreciation.\n Under normal circumstances, the fund invests at least 80% of its net assets in equity securities in the form of common stock of companies engaged in the research, development, production, sale, delivery or distribution of products and services related to the health care industry. The Adviser uses various criteria to determine whether an issuer is engaged in activities related to the health care industry. It is non-diversified.", "manager_name": "Neal  Kaufman", "manager_bio": "Mr. Kaufman has worked at BAMCO as an analyst since March of 2005. From 2001 to 2005, he worked at Credit Suisse First Boston as a vice president and managed a portfolio in the Equity Proprietary Trading group. From 1996 to 2001, Mr. Kaufman practiced corporate law in New York. He graduated cum laude from Yale College with a B.A. in History in 1993, from Columbia Law School with a J.D. in 1996 and from Columbia Business School with an Executive M.B.A. in 2002.", "category": "Health", "family": "Baron Capital Group", "exchange": "NAS", "market": "us_market"}, "BHCUX": {"short_name": "Baron Health Care Fund R6 Share", "long_name": "Baron Health Care Fund R6 Shares", "currency": "USD", "summary": "The investment seeks capital appreciation.\n Under normal circumstances, the fund invests at least 80% of its net assets in equity securities in the form of common stock of companies engaged in the research, development, production, sale, delivery or distribution of products and services related to the health care industry. The Adviser uses various criteria to determine whether an issuer is engaged in activities related to the health care industry. It is non-diversified.", "manager_name": "Neal  Kaufman", "manager_bio": "Mr. Kaufman has worked at BAMCO as an analyst since March of 2005. From 2001 to 2005, he worked at Credit Suisse First Boston as a vice president and managed a portfolio in the Equity Proprietary Trading group. From 1996 to 2001, Mr. Kaufman practiced corporate law in New York. He graduated cum laude from Yale College with a B.A. in History in 1993, from Columbia Law School with a J.D. in 1996 and from Columbia Business School with an Executive M.B.A. in 2002.", "category": "Health", "family": "Baron Capital Group", "exchange": "NAS", "market": "us_market"}, "BHSRX": {"short_name": "BlackRock Health Sciences Oppor", "long_name": "BlackRock Health Sciences Opportunities Portfolio Class R", "currency": "USD", "summary": "The investment seeks to provide long-term growth of capital.\n The fund invests at least 80% of its total assets in equity securities, primarily common stock, of companies in health sciences and related industries. The health sciences sector can include companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals. It will concentrate its investments (i.e., invest more than 25% of its assets) in health sciences or related industries, and may invest in companies located in non-U.S. countries.", "manager_name": "Xiang  Liu", "manager_bio": "Ms. Xie is the managing director and Portfolio Manager of BlackRock Advisor since 2006. Before becoming part of BlackRock Advisors in 2005, she was with State Street Research & Management since 2001. Ms. Xie began her investment career as a pharmaceutical analyst for Sanford Bernstein in 1999.", "category": "Health", "family": "BlackRock", "exchange": "NAS", "market": "us_market"}, "DLHAX": {"short_name": "Delaware Healthcare Fund Class ", "long_name": "Delaware Healthcare Fund Class A", "currency": "USD", "summary": "The investment seeks maximum long-term capital growth through capital appreciation.\n Under normal circumstances, the fund will invest at least 80% of its assets, plus the amount of any borrowings for investment purposes, in the equity securities of healthcare companies, meaning companies that develop, produce, or distribute products or services related to the healthcare or medical industries and derive a substantial portion, that is, more than 50%, of their sales from products and services in the healthcare industry (80% policy). It is non-diversified.", "manager_name": "Liu-Er  Chen", "manager_bio": "Liu-Er Chen, CFA, Senior Vice President, Chief Investment Officer \u00e2\u0080\u0094 Emerging Markets and Healthcare, is a Portfolio Manager in Delaware Investments Fund Advisers, a series of Macquarie Investment Management Business Trust. Mr. Chen heads the firm's global Emerging Markets team. Prior to joining Macquarie Investment Management (MIM) in September 2006 in his current position, Mr. Chen spent nearly 11 years at Evergreen Investment Management Company, where he most recently served as Managing Director and Senior Portfolio Manager. Mr. Chen began his career at Evergreen in 1995 as an analyst.", "category": "Health", "family": "Delaware Funds by Macquarie", "exchange": "NAS", "market": "us_market"}, "DLHCX": {"short_name": "Delaware HealthCare Fund Class ", "long_name": "Delaware Healthcare Fund Class C", "currency": "USD", "summary": "The investment seeks maximum long-term capital growth through capital appreciation.\n Under normal circumstances, the fund will invest at least 80% of its assets, plus the amount of any borrowings for investment purposes, in the equity securities of healthcare companies, meaning companies that develop, produce, or distribute products or services related to the healthcare or medical industries and derive a substantial portion, that is, more than 50%, of their sales from products and services in the healthcare industry (80% policy). It is non-diversified.", "manager_name": "Liu-Er  Chen", "manager_bio": "Liu-Er Chen, CFA, Senior Vice President, Chief Investment Officer \u00e2\u0080\u0094 Emerging Markets and Healthcare, is a Portfolio Manager in Delaware Investments Fund Advisers, a series of Macquarie Investment Management Business Trust. Mr. Chen heads the firm's global Emerging Markets team. Prior to joining Macquarie Investment Management (MIM) in September 2006 in his current position, Mr. Chen spent nearly 11 years at Evergreen Investment Management Company, where he most recently served as Managing Director and Senior Portfolio Manager. Mr. Chen began his career at Evergreen in 1995 as an analyst.", "category": "Health", "family": "Delaware Funds by Macquarie", "exchange": "NAS", "market": "us_market"}, "DLHIX": {"short_name": "Delaware Healthcare Fund Class ", "long_name": "Delaware Healthcare Fund Class I", "currency": "USD", "summary": "The investment seeks maximum long-term capital growth through capital appreciation.\n Under normal circumstances, the fund will invest at least 80% of its assets, plus the amount of any borrowings for investment purposes, in the equity securities of healthcare companies, meaning companies that develop, produce, or distribute products or services related to the healthcare or medical industries and derive a substantial portion, that is, more than 50%, of their sales from products and services in the healthcare industry (80% policy). It is non-diversified.", "manager_name": "Liu-Er  Chen", "manager_bio": "Liu-Er Chen, CFA, Senior Vice President, Chief Investment Officer \u00e2\u0080\u0094 Emerging Markets and Healthcare, is a Portfolio Manager in Delaware Investments Fund Advisers, a series of Macquarie Investment Management Business Trust. Mr. Chen heads the firm's global Emerging Markets team. Prior to joining Macquarie Investment Management (MIM) in September 2006 in his current position, Mr. Chen spent nearly 11 years at Evergreen Investment Management Company, where he most recently served as Managing Director and Senior Portfolio Manager. Mr. Chen began his career at Evergreen in 1995 as an analyst.", "category": "Health", "family": "Delaware Funds by Macquarie", "exchange": "NAS", "market": "us_market"}, "DLRHX": {"short_name": "Delaware HealthCare Fund Class ", "long_name": "Delaware Healthcare Fund Class R", "currency": "USD", "summary": "The investment seeks maximum long-term capital growth through capital appreciation.\n Under normal circumstances, the fund will invest at least 80% of its assets, plus the amount of any borrowings for investment purposes, in the equity securities of healthcare companies, meaning companies that develop, produce, or distribute products or services related to the healthcare or medical industries and derive a substantial portion, that is, more than 50%, of their sales from products and services in the healthcare industry (80% policy). It is non-diversified.", "manager_name": "Liu-Er  Chen", "manager_bio": "Liu-Er Chen, CFA, Senior Vice President, Chief Investment Officer \u00e2\u0080\u0094 Emerging Markets and Healthcare, is a Portfolio Manager in Delaware Investments Fund Advisers, a series of Macquarie Investment Management Business Trust. Mr. Chen heads the firm's global Emerging Markets team. Prior to joining Macquarie Investment Management (MIM) in September 2006 in his current position, Mr. Chen spent nearly 11 years at Evergreen Investment Management Company, where he most recently served as Managing Director and Senior Portfolio Manager. Mr. Chen began his career at Evergreen in 1995 as an analyst.", "category": "Health", "family": "Delaware Funds by Macquarie", "exchange": "NAS", "market": "us_market"}, "ETNHX": {"short_name": "Eventide Healthcare & Life Scie", "long_name": "Eventide Healthcare & Life Sciences Fund CLASS N SHARES", "currency": "USD", "summary": "The investment seeks to provide long-term capital appreciation.\n Under normal market conditions, the fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. It may invest without limitation in securities of companies domiciled outside the United States either directly or through American Depositary Receipts (\"ADRs\"). The fund may invest in securities of companies of any market capitalization.", "manager_name": "Finny  Kuruvilla", "manager_bio": "Finny Kuruvilla, M.D., Ph.D., has been primarily responsible for the day-to-day management of the Gilead Fund and Healthcare & Life Sciences Fund since inception. Dr. Kuruvilla has been the Managing Partner of the Adviser since its inception in 2008. Dr. Kuruvilla possesses a diverse background in quantitative methods, with applications focused on innovations in science, engineering, and medicine. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master\u00e2\u0080\u0099s degree in Electrical Engineering and Computer Science from MIT, and a bachelor\u00e2\u0080\u0099s degree from Caltech in Chemistry. From 2005-2008, Dr. Kuruvilla was a clinical fellow at the Brigham and Women's Hospital and a postdoctoral scientist at MIT. As an avid proponent of values-based investing, Dr. Kuruvilla has established rigorous standards in seeking out the most ethical companies at the outset of the stock selection process. In addition to his role with the Adviser, Dr. Kuruvilla is a founder, financial sponsor, and Board Director of Sattler College, a four-year college in Boston, Massachusetts, opened in 2018. Dr. Kuruvilla also contributes to the college in a limited faculty role. From 2008-2016, Dr. Kuruvilla provided research services as an employee of Clarus Ventures, a healthcare and life sciences venture capital firm. From 2006-2008, Dr. Kuruvilla was a research fellow at the Broad Institute of Harvard and MIT.", "category": "Health", "family": "Eventide Funds", "exchange": "NAS", "market": "us_market"}, "FACDX": {"short_name": "Fidelity Advisor Series VII: Fi", "long_name": "Fidelity Advisor Health Care Fund Class A", "currency": "USD", "summary": "The investment seeks capital appreciation.\n The fund normally invests primarily in common stocks. It invests at least 80% of assets in securities of companies principally engaged in the design, manufacture, or sale of products or services used for or in connection with health care or medicine. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer&#39;s financial condition and industry position, as well as market and economic conditions, to select investments.", "manager_name": "Edward L. Yoon", "manager_bio": "Edward Yoon is a manager. Since joining Fidelity Investments in 2006, Mr. Yoon has served as a research analyst and portfolio manager. Prior to joining Fidelity, he worked for JPMorgan Asset Management as a research analyst and co-fund manager from 2002 until 2006. Mr. Yoon received a BA in business economics from Brown University in 2002.", "category": "Health", "family": "Fidelity Investments", "exchange": "NAS", "market": "us_market"}, "FACTX": {"short_name": "Fidelity Advisor Health Care Fu", "long_name": "Fidelity Advisor Health Care Fund Class M", "currency": "USD", "summary": "The investment seeks capital appreciation.\n The fund normally invests primarily in common stocks. It invests at least 80% of assets in securities of companies principally engaged in the design, manufacture, or sale of products or services used for or in connection with health care or medicine. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer&#39;s financial condition and industry position, as well as market and economic conditions, to select investments.", "manager_name": "Edward L. Yoon", "manager_bio": "Edward Yoon is a manager. Since joining Fidelity Investments in 2006, Mr. Yoon has served as a research analyst and portfolio manager. Prior to joining Fidelity, he worked for JPMorgan Asset Management as a research analyst and co-fund manager from 2002 until 2006. Mr. Yoon received a BA in business economics from Brown University in 2002.", "category": "Health", "family": "Fidelity Investments", "exchange": "NAS", "market": "us_market"}, "FBIOX": {"short_name": "Fidelity Select Biotechnology P", "long_name": "Fidelity Select Biotechnology Portfolio", "currency": "USD", "summary": "The investment seeks capital appreciation.\n The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer&#39;s financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.", "manager_name": "Rajiv  Kaul", "manager_bio": "Kaul is a portfolio manager with Fidelity Investments. Since joining Fidelity Investments in 1996, he has worked as a research analyst and portfolio manager. Kaul also manages another Fidelity fund. Prior to Fidelity, Kaul worked at Mckinsey & Company. He is the recipient of the Kann Rasmusson Environment Award, the Dean's Summer Research Award and a Ford Undergraduate Fellowship.", "category": "Health", "family": "Fidelity Investments", "exchange": "NAS", "market": "us_market"}, "FHCIX": {"short_name": "Fidelity Advisor Health Care Fu", "long_name": "Fidelity Advisor Health Care Fund Class I", "currency": "USD", "summary": "The investment seeks capital appreciation.\n The fund normally invests primarily in common stocks. It invests at least 80% of assets in securities of companies principally engaged in the design, manufacture, or sale of products or services used for or in connection with health care or medicine. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer&#39;s financial condition and industry position, as well as market and economic conditions, to select investments.", "manager_name": "Edward L. Yoon", "manager_bio": "Edward Yoon is a manager. Since joining Fidelity Investments in 2006, Mr. Yoon has served as a research analyst and portfolio manager. Prior to joining Fidelity, he worked for JPMorgan Asset Management as a research analyst and co-fund manager from 2002 until 2006. Mr. Yoon received a BA in business economics from Brown University in 2002.", "category": "Health", "family": "Fidelity Investments", "exchange": "NAS", "market": "us_market"}, "FPHAX": {"short_name": "Fidelity Select Pharmaceuticals", "long_name": "Fidelity Select Pharmaceuticals Portfolio", "currency": "USD", "summary": "The investment seeks capital appreciation.\n The fund normally invests at least 80% of assets in companies engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all types. It invests in domestic and foreign issuers. The fund invests primarily in common stocks. It uses fundamental analysis of factors such as each issuer&#39;s financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.", "manager_name": "Karim  Suwwan de Felipe", "manager_bio": "Karim Suwwan de Felipe is portfolio manager of Pharmaceuticals Portfolio, which he has managed since July 2017. Since joining Fidelity Investments in 2010, Mr. Suwwan de Felipe has worked as a research analyst and portfolio manager", "category": "Health", "family": "Fidelity Investments", "exchange": "NAS", "market": "us_market"}, "FRXLX": {"short_name": "Fidelity Disruptive Medicine Fu", "long_name": "Fidelity Disruptive Medicine Fund Loyalty Class 1", "currency": "USD", "summary": "The investment seeks long-term growth of capital.\n Normally the fund invests at least 80% of assets in securities of disruptive medicine companies. Normally it invests primarily in equity securities. Companies within the disruptive medicine theme include but are not limited to those companies that, in the Adviser&#39;s opinion, are engaged in robotic surgery, gene therapy, genomics, rare diseases, medical devices and equipment, immunotherapy, technology-based health care platforms, and consumer wellness. The fund is non-diversified.", "manager_name": "Christopher T. Lee", "manager_bio": "Lee is portfolio manager at Fidelity. Since joining Fidelity in 2004 as an equity analyst, Lee has been following companies in the semiconductor sector. He previously served as an analyst intern for Minot Capital Management in Boston during the summer of 2003. From 1999 to 2002, he was an associate in the Technology Group for TA Associates, a private equity firm in Boston. Lee began his career at Robertson Stephens, where he served as a financial analyst in the Technology Group from 1997-1999.", "category": "Health", "family": "Fidelity Investments", "exchange": "NAS", "market": "us_market"}, "FSMEX": {"short_name": "Fidelity Select Portfolio Medic", "long_name": "Fidelity Select Medical Technology and Devices Portfolio", "currency": "USD", "summary": "The investment seeks capital appreciation.\n The fund normally invests at least 80% of its assets in securities of companies principally engaged in research, development, manufacture, distribution, supply, or sale of medical equipment, devices, and related technologies, companies enabling drug discovery, and companies providing information technology services primarily to health care providers. It invests primarily in common stocks. The fund invests in domestic and foreign issuers. The fund is non-diversified.", "manager_name": "Edward L. Yoon", "manager_bio": "Edward Yoon is a manager. Since joining Fidelity Investments in 2006, Mr. Yoon has served as a research analyst and portfolio manager. Prior to joining Fidelity, he worked for JPMorgan Asset Management as a research analyst and co-fund manager from 2002 until 2006. Mr. Yoon received a BA in business economics from Brown University in 2002.", "category": "Health", "family": "Fidelity Investments", "exchange": "NAS", "market": "us_market"}, "GGHCX": {"short_name": "Invesco Global Health Care Fund", "long_name": "Invesco Health Care Fund Class A", "currency": "USD", "summary": "The investment seeks long-term growth of capital.\n The fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in securities of issuers engaged primarily in health care-related industries, and in derivatives and other instruments that have economic characteristics similar to such securities. It invests primarily in equity securities, securities convertible into equity securities, and depositary receipts. The fund may invest in the securities of issuers of all capitalization sizes and may invest a significant amount of its net assets in the securities of small- and mid-capitalization issuers.", "manager_name": "Henry  Wu", "manager_bio": "Henry Wu, Portfolio Manager, has been associated with Invesco and/or its affiliates since 2014 (and was previously associated with Invesco and/or its affiliates from 2006 to 2010). From 2012 to 2013, he was employed by Scopia Capital as a senior analyst. From 2010 to 2012, he was employed by Surveyor Capital/Citdadel Investment Group as an analyst.", "category": "Health", "family": "Invesco", "exchange": "NAS", "market": "us_market"}, "HGHAX": {"short_name": "The Hartford Healthcare Fund Cl", "long_name": "The Hartford Healthcare Fund Class A", "currency": "USD", "summary": "The investment seeks long-term capital appreciation.\n Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of health care-related companies worldwide as selected by the sub-adviser, Wellington Management Company LLP (\"Wellington Management\"). The fund takes a broad approach to investing in the health care sector. It may invest in health-related companies, including companies in the pharmaceuticals, biotechnology, medical delivery, medical products, medical services, managed health care, health information services and emerging health-related subsectors.", "manager_name": "Robert L. Deresiewicz", "manager_bio": "En tant qu\u00e2\u0080\u0099analyste de la recherche sectorielle mondiale, Mme Hynes se sp\u00c3\u00a9cialise dans les secteurs des produits pharmaceutiques et de la biotechnologie. \nMme Hynes d\u00c3\u00a9tient un baccalaur\u00c3\u00a9at en \u00c3\u00a9conomie du Wellesley College (1991). Elle est entr\u00c3\u00a9e au service de Wellington Management imm\u00c3\u00a9diatement apr\u00c3\u00a8s l\u00e2\u0080\u0099obtention de son dipl\u00c3\u00b4me. Elle d\u00c3\u00a9tient le titre d\u00e2\u0080\u0099analyste financi\u00c3\u00a8re agr\u00c3\u00a9\u00c3\u00a9e, et est membre du CFA Institute et de la Boston Security Analysts Society.", "category": "Health", "family": "Hartford Mutual Funds", "exchange": "NAS", "market": "us_market"}, "HGHRX": {"short_name": "The Hartford Healthcare Fund Cl", "long_name": "The Hartford Healthcare Fund Class R3", "currency": "USD", "summary": "The investment seeks long-term capital appreciation.\n Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of health care-related companies worldwide as selected by the sub-adviser, Wellington Management Company LLP (\"Wellington Management\"). The fund takes a broad approach to investing in the health care sector. It may invest in health-related companies, including companies in the pharmaceuticals, biotechnology, medical delivery, medical products, medical services, managed health care, health information services and emerging health-related subsectors.", "manager_name": "Robert L. Deresiewicz", "manager_bio": "En tant qu\u00e2\u0080\u0099analyste de la recherche sectorielle mondiale, Mme Hynes se sp\u00c3\u00a9cialise dans les secteurs des produits pharmaceutiques et de la biotechnologie. \nMme Hynes d\u00c3\u00a9tient un baccalaur\u00c3\u00a9at en \u00c3\u00a9conomie du Wellesley College (1991). Elle est entr\u00c3\u00a9e au service de Wellington Management imm\u00c3\u00a9diatement apr\u00c3\u00a8s l\u00e2\u0080\u0099obtention de son dipl\u00c3\u00b4me. Elle d\u00c3\u00a9tient le titre d\u00e2\u0080\u0099analyste financi\u00c3\u00a8re agr\u00c3\u00a9\u00c3\u00a9e, et est membre du CFA Institute et de la Boston Security Analysts Society.", "category": "Health", "family": "Hartford Mutual Funds", "exchange": "NAS", "market": "us_market"}, "HGHSX": {"short_name": "The Hartford Healthcare Fund Cl", "long_name": "The Hartford Healthcare Fund Class R4", "currency": "USD", "summary": "The investment seeks long-term capital appreciation.\n Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of health care-related companies worldwide as selected by the sub-adviser, Wellington Management Company LLP (\"Wellington Management\"). The fund takes a broad approach to investing in the health care sector. It may invest in health-related companies, including companies in the pharmaceuticals, biotechnology, medical delivery, medical products, medical services, managed health care, health information services and emerging health-related subsectors.", "manager_name": "Robert L. Deresiewicz", "manager_bio": "En tant qu\u00e2\u0080\u0099analyste de la recherche sectorielle mondiale, Mme Hynes se sp\u00c3\u00a9cialise dans les secteurs des produits pharmaceutiques et de la biotechnologie. \nMme Hynes d\u00c3\u00a9tient un baccalaur\u00c3\u00a9at en \u00c3\u00a9conomie du Wellesley College (1991). Elle est entr\u00c3\u00a9e au service de Wellington Management imm\u00c3\u00a9diatement apr\u00c3\u00a8s l\u00e2\u0080\u0099obtention de son dipl\u00c3\u00b4me. Elle d\u00c3\u00a9tient le titre d\u00e2\u0080\u0099analyste financi\u00c3\u00a8re agr\u00c3\u00a9\u00c3\u00a9e, et est membre du CFA Institute et de la Boston Security Analysts Society.", "category": "Health", "family": "Hartford Mutual Funds", "exchange": "NAS", "market": "us_market"}, "JFNAX": {"short_name": "Janus Henderson Global Life Sci", "long_name": "Janus Henderson Global Life Sciences Fund Class A", "currency": "USD", "summary": "The investment seeks long-term growth of capital.\n The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio managers believe have a life science orientation. In the fund&#39;s pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the \"life sciences\" sector.", "manager_name": "Andrew  Acker", "manager_bio": "Andy Acker is a Portfolio Manager at Janus Henderson Investors responsible for managing the Global Life Sciences and Biotechnology strategies since 2007 and 2018, respectively. He also leads the firm\u00e2\u0080\u0099s Health Care Sector Research Team. Andy was assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners. Andy received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation and has 23 years of financial industry experience.", "category": "Health", "family": "Janus Henderson", "exchange": "NAS", "market": "us_market"}, "JFNCX": {"short_name": "Janus Henderson Global Life Sci", "long_name": "Janus Henderson Global Life Sciences Fund Class C", "currency": "USD", "summary": "The investment seeks long-term growth of capital.\n The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio managers believe have a life science orientation. In the fund&#39;s pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the \"life sciences\" sector.", "manager_name": "Andrew  Acker", "manager_bio": "Andy Acker is a Portfolio Manager at Janus Henderson Investors responsible for managing the Global Life Sciences and Biotechnology strategies since 2007 and 2018, respectively. He also leads the firm\u00e2\u0080\u0099s Health Care Sector Research Team. Andy was assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners. Andy received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation and has 23 years of financial industry experience.", "category": "Health", "family": "Janus Henderson", "exchange": "NAS", "market": "us_market"}, "JFNIX": {"short_name": "Janus Henderson Global Life Sci", "long_name": "Janus Henderson Global Life Sciences Fund Class I", "currency": "USD", "summary": "The investment seeks long-term growth of capital.\n The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio managers believe have a life science orientation. In the fund&#39;s pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the \"life sciences\" sector.", "manager_name": "Andrew  Acker", "manager_bio": "Andy Acker is a Portfolio Manager at Janus Henderson Investors responsible for managing the Global Life Sciences and Biotechnology strategies since 2007 and 2018, respectively. He also leads the firm\u00e2\u0080\u0099s Health Care Sector Research Team. Andy was assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners. Andy received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation and has 23 years of financial industry experience.", "category": "Health", "family": "Janus Henderson", "exchange": "NAS", "market": "us_market"}, "LHCQX": {"short_name": "Lord Abbett Health Care Fund - ", "long_name": "Lord Abbett Health Care Fund Class R3", "currency": "USD", "summary": "The investment seeks long-term capital appreciation.\n Under normal conditions, the fund will invest at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in equity and equity-related securities of health care-related companies. The Advisor considers health care-related companies to be those companies that operate in, or are related to, the major subsectors of the health care sector, including pharmaceuticals, biotechnology, health care technology, life sciences tools and services, health care equipment and supplies, and health care providers and services.", "manager_name": "Matthew R. DeCicco", "manager_bio": "Mr. DeCicco is a holder of a Chartered Financial Analyst designation and joined Lord Abbett in 1999. He has been a member of the team since 2002 and assumed Portfolio Manager in 2015.", "category": "Health", "family": "Lord Abbett", "exchange": "NAS", "market": "us_market"}, "LOGSX": {"short_name": "Live Oak Health Sciences Fund", "long_name": "Live Oak Health Sciences Fund", "currency": "USD", "summary": "The investment seeks long-term capital growth.\n The fund invests primarily in common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences. It will invest at least 80% of its net assets, under normal circumstances, in equity securities of health science companies. The fund invests primarily in common stocks of U.S. companies, but may, to a lesser extent, invest in equity REITs, common stocks of foreign companies and American Depositary Receipts (\"ADRs\") that meet the investment criteria of the fund.", "manager_name": "James D. Oelschlager", "manager_bio": "James D. Oelschlager serves as Co-Chief Investment Officer of Oak Associates ltd. He previously served as the President and CIO of Oak Associates and its predecessor from 1985-2019. Prior to founding Oak Associates in 1985, Mr. Oelschlager served as Director of Pension Investments/Assistant Treasurer for the Firestone Tire & Rubber Company. He has been with the investment industry since 1970.", "category": "Health", "family": "Oak Associates", "exchange": "NAS", "market": "us_market"}, "MEDRX": {"short_name": "Kinetics Mutual Funds, Inc. The", "long_name": "Kinetics Medical Fund No Load Class", "currency": "USD", "summary": "The investment seeks long-term growth of capital.\n The fund is a non-diversified fund that invests all of its investable assets in the Medical Portfolio, a series of Kinetics Portfolios Trust. The Portfolio invests at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants, and other equity securities having the characteristics of common stocks of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries, with an emphasis toward companies engaged in cancer research and drug development. It is non-diversified.", "manager_name": "Bruce P. Abel", "manager_bio": "Mr. Abel is a portfolio manager with Kinetics Asset Management, his employer since 1999. Prior to joining the firm, he was employed with Brookhaven National Laboratory since 1989 where he worked researching, developing and implementing technical and scientific programs and systems in the areas of nuclear physics and computer programming, and industrial design. He has over 10 years experience in the fields of science, chemistry, physics, and engineering.", "category": "Health", "family": "Kinetics", "exchange": "NAS", "market": "us_market"}, "PCHSX": {"short_name": "Putnam Global Health Care Fund ", "long_name": "Putnam Global Health Care Fund Class C", "currency": "USD", "summary": "The investment seeks capital appreciation.\n The fund invests mainly in common stocks (growth or value stocks or both) of large and midsize companies worldwide that the manager believes have favorable investment potential. Under normal circumstances, it invests at least 80% of its net assets in securities of companies in the health care industries. The fund is non-diversified.", "manager_name": "Michael  Maguire", "manager_bio": "", "category": "Health", "family": "Putnam", "exchange": "NAS", "market": "us_market"}, "PDFDX": {"short_name": "Perkins Discovery Fd", "long_name": "Perkins Discovery Fund", "currency": "USD", "summary": "The investment seeks long-term capital appreciation.\n The fund will invest, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in equity securities of domestic companies with market capitalizations of under $1 billion at the time of purchase. The equity securities the fund may purchase consist mostly of common stock, although the fund may purchase preferred and convertible stocks.", "manager_name": "Daniel S. Perkins", "manager_bio": "Mr. Daniel S. Perkins has been associated with the Perkins Capital Management since 1984. Mr. Richard C. Perkins has been associated with the Perkins Capital Management since 1990.\n\nMr. Daniel S. Perkins, CFA, is the Chief Operating Officer of the Perkins Capital Management. He previously served as the Executive Vice President of the Perkins Capital Management from 2005-2019 and was Vice President prior to 2005 for over 20 years. Prior to becoming a portfolio manager and Vice President of the Perkins Capital Management, he was employed as a financial analyst at Perkins and Partners, Inc. Mr. Daniel S. Perkins earned a BS in Business Administration from the University of Colorado-Boulder and an MBA in Finance from the University of Minnesota.", "category": "Health", "family": "Perkins", "exchange": "NAS", "market": "us_market"}, "PGHAX": {"short_name": "Putnam Global Healthcare Class ", "long_name": "Putnam Global Health Care Fund Class R6 Shares", "currency": "USD", "summary": "The investment seeks capital appreciation.\n The fund invests mainly in common stocks (growth or value stocks or both) of large and midsize companies worldwide that the manager believes have favorable investment potential. Under normal circumstances, it invests at least 80% of its net assets in securities of companies in the health care industries. The fund is non-diversified.", "manager_name": "Michael  Maguire", "manager_bio": "", "category": "Health", "family": "Putnam", "exchange": "NAS", "market": "us_market"}, "PHLCX": {"short_name": "PGIM Jennison Health Sciences F", "long_name": "PGIM Jennison Health Sciences Fund- Class C", "currency": "USD", "summary": "The investment seeks long-term capital appreciation.\n The fund seeks investments whose prices will increase over time. It normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the healthcare sector. The fund is non-diversified.", "manager_name": "David  Chan", "manager_bio": "David Chan, CFA, is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Mr. Chan joined Jennison Associates in May 1992. He was previously with the Boston Consulting Group, where he was a team leader and consultant on projects in a wide variety of industries, but with a special focus in the health care area. Mr. Chan has also worked in various positions in the film and television industry. He received a BA in biochemistry from Harvard University and an MBA from Columbia University.", "category": "Health", "family": "PGIM Funds (Prudential)", "exchange": "NAS", "market": "us_market"}, "PHLQX": {"short_name": "PGIM Jennison Health Sciences F", "long_name": "PGIM Jennison Health Sciences Fund- Class R6", "currency": "USD", "summary": "The investment seeks long-term capital appreciation.\n The fund seeks investments whose prices will increase over time. It normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the healthcare sector. The fund is non-diversified.", "manager_name": "David  Chan", "manager_bio": "David Chan, CFA, is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Mr. Chan joined Jennison Associates in May 1992. He was previously with the Boston Consulting Group, where he was a team leader and consultant on projects in a wide variety of industries, but with a special focus in the health care area. Mr. Chan has also worked in various positions in the film and television industry. He received a BA in biochemistry from Harvard University and an MBA from Columbia University.", "category": "Health", "family": "PGIM Funds (Prudential)", "exchange": "NAS", "market": "us_market"}, "PHSBX": {"short_name": "Putnam Global Health Care Fund ", "long_name": "Putnam Global Health Care Fund Class B", "currency": "USD", "summary": "The investment seeks capital appreciation.\n The fund invests mainly in common stocks (growth or value stocks or both) of large and midsize companies worldwide that the manager believes have favorable investment potential. Under normal circumstances, it invests at least 80% of its net assets in securities of companies in the health care industries. The fund is non-diversified.", "manager_name": "Michael  Maguire", "manager_bio": "", "category": "Health", "family": "Putnam", "exchange": "NAS", "market": "us_market"}, "PHSRX": {"short_name": "Putnam Global Health Care Fund ", "long_name": "Putnam Global Health Care Fund Class R", "currency": "USD", "summary": "The investment seeks capital appreciation.\n The fund invests mainly in common stocks (growth or value stocks or both) of large and midsize companies worldwide that the manager believes have favorable investment potential. Under normal circumstances, it invests at least 80% of its net assets in securities of companies in the health care industries. The fund is non-diversified.", "manager_name": "Michael  Maguire", "manager_bio": "", "category": "Health", "family": "Putnam", "exchange": "NAS", "market": "us_market"}, "PHSTX": {"short_name": "Putnam Global Health Care Fund ", "long_name": "Putnam Global Health Care Fund Class A", "currency": "USD", "summary": "The investment seeks capital appreciation.\n The fund invests mainly in common stocks (growth or value stocks or both) of large and midsize companies worldwide that the manager believes have favorable investment potential. Under normal circumstances, it invests at least 80% of its net assets in securities of companies in the health care industries. The fund is non-diversified.", "manager_name": "Michael  Maguire", "manager_bio": "", "category": "Health", "family": "Putnam", "exchange": "NAS", "market": "us_market"}, "PHSYX": {"short_name": "Putnam Global Health Care Fund ", "long_name": "Putnam Global Health Care Fund Class Y", "currency": "USD", "summary": "The investment seeks capital appreciation.\n The fund invests mainly in common stocks (growth or value stocks or both) of large and midsize companies worldwide that the manager believes have favorable investment potential. Under normal circumstances, it invests at least 80% of its net assets in securities of companies in the health care industries. The fund is non-diversified.", "manager_name": "Michael  Maguire", "manager_bio": "", "category": "Health", "family": "Putnam", "exchange": "NAS", "market": "us_market"}, "PHSZX": {"short_name": "PGIM Jennison Health Sciences F", "long_name": "PGIM Jennison Health Sciences Fund- Class Z", "currency": "USD", "summary": "The investment seeks long-term capital appreciation.\n The fund seeks investments whose prices will increase over time. It normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the healthcare sector. The fund is non-diversified.", "manager_name": "David  Chan", "manager_bio": "David Chan, CFA, is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Mr. Chan joined Jennison Associates in May 1992. He was previously with the Boston Consulting Group, where he was a team leader and consultant on projects in a wide variety of industries, but with a special focus in the health care area. Mr. Chan has also worked in various positions in the film and television industry. He received a BA in biochemistry from Harvard University and an MBA from Columbia University.", "category": "Health", "family": "PGIM Funds (Prudential)", "exchange": "NAS", "market": "us_market"}, "PJHRX": {"short_name": "PGIM Jennison Health Sciences F", "long_name": "PGIM Jennison Health Sciences Fund- Class R", "currency": "USD", "summary": "The investment seeks long-term capital appreciation.\n The fund seeks investments whose prices will increase over time. It normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the healthcare sector. The fund is non-diversified.", "manager_name": "David  Chan", "manager_bio": "David Chan, CFA, is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Mr. Chan joined Jennison Associates in May 1992. He was previously with the Boston Consulting Group, where he was a team leader and consultant on projects in a wide variety of industries, but with a special focus in the health care area. Mr. Chan has also worked in various positions in the film and television industry. He received a BA in biochemistry from Harvard University and an MBA from Columbia University.", "category": "Health", "family": "PGIM Funds (Prudential)", "exchange": "NAS", "market": "us_market"}, "PRHSX": {"short_name": "T. Rowe Price Health Sciences F", "long_name": "T. Rowe Price Health Sciences Fund", "currency": "USD", "summary": "The investment seeks long-term capital appreciation.\n The fund will normally invest at least 80% of its net assets (including any borrowings for investment purposes) in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed \"health sciences\"). While the fund can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-capitalization companies. It is non-diversified.", "manager_name": "Ziad  Bakri", "manager_bio": "Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment ban", "category": "Health", "family": "T. Rowe Price", "exchange": "NAS", "market": "us_market"}, "RAGHX": {"short_name": "AllianzGI Health Sciences Fund ", "long_name": "AllianzGI Health Sciences Fund Class A", "currency": "USD", "summary": "The investment seeks long-term capital appreciation.\n The fund seeks to achieve its objective by normally investing at least 80% of its net assets (plus borrowings made for investment purposes) in health sciences-related companies. The portfolio manager considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences. The fund will invest primarily in common stocks and other equity securities.", "manager_name": "Peter  Pirsch", "manager_bio": "Mr. Pirsch, CFA, is a senior portfolio manager, a senior analyst and a director with Allianz Global Investors, which he joined in 2018. He has management and research responsibilities for the Health Care team. Mr. Pirsch has 19 years of investment-industry experience. He previously worked at Aptigon Capital, Visium Asset Management, Surveyor Capital, Fred Alger Management and C.R. Bard. Before that, Mr. Pirsch was an analyst at UBS Investment Bank and Wells Fargo. He has a B.A. in economics and international relations from Bucknell University and an M.B.A. from Duke University, Fuqua School of Business. Mr. Pirsch is a CFA charterholder", "category": "Health", "family": "Allianz Global Investors", "exchange": "NAS", "market": "us_market"}, "RCGHX": {"short_name": "AllianzGI Health Sciences Fund ", "long_name": "AllianzGI Health Sciences Fund Class C", "currency": "USD", "summary": "The investment seeks long-term capital appreciation.\n The fund seeks to achieve its objective by normally investing at least 80% of its net assets (plus borrowings made for investment purposes) in health sciences-related companies. The portfolio manager considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences. The fund will invest primarily in common stocks and other equity securities.", "manager_name": "Peter  Pirsch", "manager_bio": "Mr. Pirsch, CFA, is a senior portfolio manager, a senior analyst and a director with Allianz Global Investors, which he joined in 2018. He has management and research responsibilities for the Health Care team. Mr. Pirsch has 19 years of investment-industry experience. He previously worked at Aptigon Capital, Visium Asset Management, Surveyor Capital, Fred Alger Management and C.R. Bard. Before that, Mr. Pirsch was an analyst at UBS Investment Bank and Wells Fargo. He has a B.A. in economics and international relations from Bucknell University and an M.B.A. from Duke University, Fuqua School of Business. Mr. Pirsch is a CFA charterholder", "category": "Health", "family": "Allianz Global Investors", "exchange": "NAS", "market": "us_market"}, "RYBOX": {"short_name": "Rydex Series Fds, Biotechnology", "long_name": "Rydex Biotechnology Fund Class A", "currency": "USD", "summary": "The investment seeks to provide capital appreciation.\n Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.", "manager_name": "Michael P. Byrum", "manager_bio": "Michael P. Byrum, CFA, Senior Vice President\u00e2\u0080\u0094Mr. Byrum has been associated with the Security Investors since 1993. Mr. Byrum was the inaugural portfolio manager for many of the Rydex products, including the Rydex leveraged and inverse funds, sector fund lineup and alternative investment portfolios. Today, Mr. Byrum continues to play an instrumental role in product development and investment strategy at Guggenheim Investments and oversees the trading, research and portfolio management activities of the quantitative strategies team, which focuses on target beta, alternative and asset allocation strategies.\n He is the chairman of the Investment Strategy Committee and is a member of the Risk Management Committee and Credit Review Committee. \nPrior to joining the Security Investors\u00ef\u00bc\u008c Mr. Byrum served in a brokerage capacity with Money Management Associates, the registered investment advisor to Rushmore Funds, Inc. \nHe earned a B.S. in finance from the Miami University of Ohio. He also has earned the right to use the Chartered Financial Analyst\u00c2\u00ae designation and is a member of the CFA Institute and the CFA Society of Washington.", "category": "Health", "family": "Rydex Funds", "exchange": "NAS", "market": "us_market"}, "RYCFX": {"short_name": "Rydex Biotechnology Fund - C Cl", "long_name": "Rydex Biotechnology Fund Class C", "currency": "USD", "summary": "The investment seeks to provide capital appreciation.\n Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.", "manager_name": "Michael P. Byrum", "manager_bio": "Michael P. Byrum, CFA, Senior Vice President\u00e2\u0080\u0094Mr. Byrum has been associated with the Security Investors since 1993. Mr. Byrum was the inaugural portfolio manager for many of the Rydex products, including the Rydex leveraged and inverse funds, sector fund lineup and alternative investment portfolios. Today, Mr. Byrum continues to play an instrumental role in product development and investment strategy at Guggenheim Investments and oversees the trading, research and portfolio management activities of the quantitative strategies team, which focuses on target beta, alternative and asset allocation strategies.\n He is the chairman of the Investment Strategy Committee and is a member of the Risk Management Committee and Credit Review Committee. \nPrior to joining the Security Investors\u00ef\u00bc\u008c Mr. Byrum served in a brokerage capacity with Money Management Associates, the registered investment advisor to Rushmore Funds, Inc. \nHe earned a B.S. in finance from the Miami University of Ohio. He also has earned the right to use the Chartered Financial Analyst\u00c2\u00ae designation and is a member of the CFA Institute and the CFA Society of Washington.", "category": "Health", "family": "Rydex Funds", "exchange": "NAS", "market": "us_market"}, "RYHAX": {"short_name": "Rydex Series Fds, Health Care F", "long_name": "Rydex Health Care Fund Class H", "currency": "USD", "summary": "The investment seeks capital appreciation.\n Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Health Care Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Health Care Companies that have small to mid-sized capitalizations. The fund also may purchase American Depositary Receipts (\"ADRs\") to gain exposure to foreign Health Care Companies and U.S. government securities.", "manager_name": "Michael P. Byrum", "manager_bio": "Michael P. Byrum, CFA, Senior Vice President\u00e2\u0080\u0094Mr. Byrum has been associated with the Security Investors since 1993. Mr. Byrum was the inaugural portfolio manager for many of the Rydex products, including the Rydex leveraged and inverse funds, sector fund lineup and alternative investment portfolios. Today, Mr. Byrum continues to play an instrumental role in product development and investment strategy at Guggenheim Investments and oversees the trading, research and portfolio management activities of the quantitative strategies team, which focuses on target beta, alternative and asset allocation strategies.\n He is the chairman of the Investment Strategy Committee and is a member of the Risk Management Committee and Credit Review Committee. \nPrior to joining the Security Investors\u00ef\u00bc\u008c Mr. Byrum served in a brokerage capacity with Money Management Associates, the registered investment advisor to Rushmore Funds, Inc. \nHe earned a B.S. in finance from the Miami University of Ohio. He also has earned the right to use the Chartered Financial Analyst\u00c2\u00ae designation and is a member of the CFA Institute and the CFA Society of Washington.", "category": "Health", "family": "Rydex Funds", "exchange": "NAS", "market": "us_market"}, "RYHCX": {"short_name": "Rydex Health Care - C Class", "long_name": "Rydex Health Care Fund Class C", "currency": "USD", "summary": "The investment seeks capital appreciation.\n Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Health Care Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Health Care Companies that have small to mid-sized capitalizations. The fund also may purchase American Depositary Receipts (\"ADRs\") to gain exposure to foreign Health Care Companies and U.S. government securities.", "manager_name": "Michael P. Byrum", "manager_bio": "Michael P. Byrum, CFA, Senior Vice President\u00e2\u0080\u0094Mr. Byrum has been associated with the Security Investors since 1993. Mr. Byrum was the inaugural portfolio manager for many of the Rydex products, including the Rydex leveraged and inverse funds, sector fund lineup and alternative investment portfolios. Today, Mr. Byrum continues to play an instrumental role in product development and investment strategy at Guggenheim Investments and oversees the trading, research and portfolio management activities of the quantitative strategies team, which focuses on target beta, alternative and asset allocation strategies.\n He is the chairman of the Investment Strategy Committee and is a member of the Risk Management Committee and Credit Review Committee. \nPrior to joining the Security Investors\u00ef\u00bc\u008c Mr. Byrum served in a brokerage capacity with Money Management Associates, the registered investment advisor to Rushmore Funds, Inc. \nHe earned a B.S. in finance from the Miami University of Ohio. He also has earned the right to use the Chartered Financial Analyst\u00c2\u00ae designation and is a member of the CFA Institute and the CFA Society of Washington.", "category": "Health", "family": "Rydex Funds", "exchange": "NAS", "market": "us_market"}, "RYHEX": {"short_name": "Rydex Series Fds, Health Care F", "long_name": "Rydex Health Care Fund Class A", "currency": "USD", "summary": "The investment seeks capital appreciation.\n Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Health Care Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Health Care Companies that have small to mid-sized capitalizations. The fund also may purchase American Depositary Receipts (\"ADRs\") to gain exposure to foreign Health Care Companies and U.S. government securities.", "manager_name": "Michael P. Byrum", "manager_bio": "Michael P. Byrum, CFA, Senior Vice President\u00e2\u0080\u0094Mr. Byrum has been associated with the Security Investors since 1993. Mr. Byrum was the inaugural portfolio manager for many of the Rydex products, including the Rydex leveraged and inverse funds, sector fund lineup and alternative investment portfolios. Today, Mr. Byrum continues to play an instrumental role in product development and investment strategy at Guggenheim Investments and oversees the trading, research and portfolio management activities of the quantitative strategies team, which focuses on target beta, alternative and asset allocation strategies.\n He is the chairman of the Investment Strategy Committee and is a member of the Risk Management Committee and Credit Review Committee. \nPrior to joining the Security Investors\u00ef\u00bc\u008c Mr. Byrum served in a brokerage capacity with Money Management Associates, the registered investment advisor to Rushmore Funds, Inc. \nHe earned a B.S. in finance from the Miami University of Ohio. He also has earned the right to use the Chartered Financial Analyst\u00c2\u00ae designation and is a member of the CFA Institute and the CFA Society of Washington.", "category": "Health", "family": "Rydex Funds", "exchange": "NAS", "market": "us_market"}, "RYHIX": {"short_name": "Rydex Series Trust Health Care ", "long_name": "Rydex Health Care Fund Class Investor", "currency": "USD", "summary": "The investment seeks capital appreciation.\n Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Health Care Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Health Care Companies that have small to mid-sized capitalizations. The fund also may purchase American Depositary Receipts (\"ADRs\") to gain exposure to foreign Health Care Companies and U.S. government securities.", "manager_name": "Michael P. Byrum", "manager_bio": "Michael P. Byrum, CFA, Senior Vice President\u00e2\u0080\u0094Mr. Byrum has been associated with the Security Investors since 1993. Mr. Byrum was the inaugural portfolio manager for many of the Rydex products, including the Rydex leveraged and inverse funds, sector fund lineup and alternative investment portfolios. Today, Mr. Byrum continues to play an instrumental role in product development and investment strategy at Guggenheim Investments and oversees the trading, research and portfolio management activities of the quantitative strategies team, which focuses on target beta, alternative and asset allocation strategies.\n He is the chairman of the Investment Strategy Committee and is a member of the Risk Management Committee and Credit Review Committee. \nPrior to joining the Security Investors\u00ef\u00bc\u008c Mr. Byrum served in a brokerage capacity with Money Management Associates, the registered investment advisor to Rushmore Funds, Inc. \nHe earned a B.S. in finance from the Miami University of Ohio. He also has earned the right to use the Chartered Financial Analyst\u00c2\u00ae designation and is a member of the CFA Institute and the CFA Society of Washington.", "category": "Health", "family": "Rydex Funds", "exchange": "NAS", "market": "us_market"}, "RYOAX": {"short_name": "Rydex Series Fds, Biotechnology", "long_name": "Rydex Biotechnology Fund Class H", "currency": "USD", "summary": "The investment seeks to provide capital appreciation.\n Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.", "manager_name": "Michael P. Byrum", "manager_bio": "Michael P. Byrum, CFA, Senior Vice President\u00e2\u0080\u0094Mr. Byrum has been associated with the Security Investors since 1993. Mr. Byrum was the inaugural portfolio manager for many of the Rydex products, including the Rydex leveraged and inverse funds, sector fund lineup and alternative investment portfolios. Today, Mr. Byrum continues to play an instrumental role in product development and investment strategy at Guggenheim Investments and oversees the trading, research and portfolio management activities of the quantitative strategies team, which focuses on target beta, alternative and asset allocation strategies.\n He is the chairman of the Investment Strategy Committee and is a member of the Risk Management Committee and Credit Review Committee. \nPrior to joining the Security Investors\u00ef\u00bc\u008c Mr. Byrum served in a brokerage capacity with Money Management Associates, the registered investment advisor to Rushmore Funds, Inc. \nHe earned a B.S. in finance from the Miami University of Ohio. He also has earned the right to use the Chartered Financial Analyst\u00c2\u00ae designation and is a member of the CFA Institute and the CFA Society of Washington.", "category": "Health", "family": "Rydex Funds", "exchange": "NAS", "market": "us_market"}, "RYOIX": {"short_name": "Rydex Series Trust Biotechnolog", "long_name": "Rydex Biotechnology Fund Class Investor", "currency": "USD", "summary": "The investment seeks to provide capital appreciation.\n Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.", "manager_name": "Michael P. Byrum", "manager_bio": "Michael P. Byrum, CFA, Senior Vice President\u00e2\u0080\u0094Mr. Byrum has been associated with the Security Investors since 1993. Mr. Byrum was the inaugural portfolio manager for many of the Rydex products, including the Rydex leveraged and inverse funds, sector fund lineup and alternative investment portfolios. Today, Mr. Byrum continues to play an instrumental role in product development and investment strategy at Guggenheim Investments and oversees the trading, research and portfolio management activities of the quantitative strategies team, which focuses on target beta, alternative and asset allocation strategies.\n He is the chairman of the Investment Strategy Committee and is a member of the Risk Management Committee and Credit Review Committee. \nPrior to joining the Security Investors\u00ef\u00bc\u008c Mr. Byrum served in a brokerage capacity with Money Management Associates, the registered investment advisor to Rushmore Funds, Inc. \nHe earned a B.S. in finance from the Miami University of Ohio. He also has earned the right to use the Chartered Financial Analyst\u00c2\u00ae designation and is a member of the CFA Institute and the CFA Society of Washington.", "category": "Health", "family": "Rydex Funds", "exchange": "NAS", "market": "us_market"}, "SBHIX": {"short_name": "Saratoga Advantage Trust: Healt", "long_name": "Saratoga Health & Biotechnology Portfolio Fund Class Institutional", "currency": "USD", "summary": "The investment seeks long-term capital growth.\n The fund will normally invest at least 80% of its total assets in equity securities of U.S. and foreign healthcare companies and biotechnology companies, regardless of their stock market value (or \"market capitalization\"). Equity securities include common stocks, preferred stocks, securities convertible into common stocks and warrants. The Adviser utilizes a top-down investment approach focused on long-term economic trends.", "manager_name": "Robert D. Stimpson", "manager_bio": "Robert D. Stimpson, CFA, CMT. Mr. Stimpson is Co-Chief Investment Officer and a Portfolio Manager at Oak Associates, which he joined in 2001. Prior to joining Oak Associates in 2001, Mr. Stimpson earned an MBA from Emory University. Previously, Mr. Stimpson worked as an Equity Market Analyst for I.D.E.A., ltd and for Merrill Lynch as a Financial Consultant. He has been with the investment industry since 1997. In addition to the CFA designation, Mr. Stimpson holds the CMT charter from the Market Technicians Association.", "category": "Health", "family": "Saratoga", "exchange": "NAS", "market": "us_market"}, "SCHLX": {"short_name": "DWS Health and Wellness Fund - ", "long_name": "DWS Health and Wellness Fund - Class S", "currency": "USD", "summary": "The investment seeks long-term growth of capital.\n Under normal circumstances, the fund will invest at least 80% of net assets, plus the amount of any borrowings for investment purposes, in equity securities of companies in the health care and wellness sectors. It invests primarily in securities of U.S. companies, but may invest in foreign companies as well. The fund may invest in companies of any size. While the fund invests mainly in common stocks, it may also invest up to 20% of total assets in U.S. Treasury and U.S. agency debt obligations.", "manager_name": "Leefin  Lai", "manager_bio": "Lai ,CFA and CPA, is managing director and lead portfolio manager. Joined Deutsche Asset Management in 2001, previously serving as an analyst for Salomon Smith Barney and Paine Webber and as vice president/analyst for Citigroup Global Asset Management and Scudder Kemper Investments. Lai holds the Chartered Financial Analyst designation. Hold a BS and MBA at University of Illinois.", "category": "Health", "family": "DWS", "exchange": "NAS", "market": "us_market"}, "SHISX": {"short_name": "BlackRock HlthSc Op Svc", "long_name": "BlackRock Health Sciences Opportunities Portfolio Service Shares", "currency": "USD", "summary": "The investment seeks to provide long-term growth of capital.\n The fund invests at least 80% of its total assets in equity securities, primarily common stock, of companies in health sciences and related industries. The health sciences sector can include companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals. It will concentrate its investments (i.e., invest more than 25% of its assets) in health sciences or related industries, and may invest in companies located in non-U.S. countries.", "manager_name": "Xiang  Liu", "manager_bio": "Ms. Xie is the managing director and Portfolio Manager of BlackRock Advisor since 2006. Before becoming part of BlackRock Advisors in 2005, she was with State Street Research & Management since 2001. Ms. Xie began her investment career as a pharmaceutical analyst for Sanford Bernstein in 1999.", "category": "Health", "family": "BlackRock", "exchange": "NAS", "market": "us_market"}, "SHPAX": {"short_name": "Saratoga Advantage Tr Health & ", "long_name": "Saratoga Health & Biotechnology Portfolio Fund Class A", "currency": "USD", "summary": "The investment seeks long-term capital growth.\n The fund will normally invest at least 80% of its total assets in equity securities of U.S. and foreign healthcare companies and biotechnology companies, regardless of their stock market value (or \"market capitalization\"). Equity securities include common stocks, preferred stocks, securities convertible into common stocks and warrants. The Adviser utilizes a top-down investment approach focused on long-term economic trends.", "manager_name": "Robert D. Stimpson", "manager_bio": "Robert D. Stimpson, CFA, CMT. Mr. Stimpson is Co-Chief Investment Officer and a Portfolio Manager at Oak Associates, which he joined in 2001. Prior to joining Oak Associates in 2001, Mr. Stimpson earned an MBA from Emory University. Previously, Mr. Stimpson worked as an Equity Market Analyst for I.D.E.A., ltd and for Merrill Lynch as a Financial Consultant. He has been with the investment industry since 1997. In addition to the CFA designation, Mr. Stimpson holds the CMT charter from the Market Technicians Association.", "category": "Health", "family": "Saratoga", "exchange": "NAS", "market": "us_market"}, "SHPCX": {"short_name": "Saratoga Advantage Tr Health & ", "long_name": "Saratoga Health & Biotechnology Portfolio Fund Class C", "currency": "USD", "summary": "The investment seeks long-term capital growth.\n The fund will normally invest at least 80% of its total assets in equity securities of U.S. and foreign healthcare companies and biotechnology companies, regardless of their stock market value (or \"market capitalization\"). Equity securities include common stocks, preferred stocks, securities convertible into common stocks and warrants. The Adviser utilizes a top-down investment approach focused on long-term economic trends.", "manager_name": "Robert D. Stimpson", "manager_bio": "Robert D. Stimpson, CFA, CMT. Mr. Stimpson is Co-Chief Investment Officer and a Portfolio Manager at Oak Associates, which he joined in 2001. Prior to joining Oak Associates in 2001, Mr. Stimpson earned an MBA from Emory University. Previously, Mr. Stimpson worked as an Equity Market Analyst for I.D.E.A., ltd and for Merrill Lynch as a Financial Consultant. He has been with the investment industry since 1997. In addition to the CFA designation, Mr. Stimpson holds the CMT charter from the Market Technicians Association.", "category": "Health", "family": "Saratoga", "exchange": "NAS", "market": "us_market"}, "SHSAX": {"short_name": "BlackRock HlthSc Op A", "long_name": "BlackRock Health Sciences Opportunities Portfolio Investor A Shares", "currency": "USD", "summary": "The investment seeks to provide long-term growth of capital.\n The fund invests at least 80% of its total assets in equity securities, primarily common stock, of companies in health sciences and related industries. The health sciences sector can include companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals. It will concentrate its investments (i.e., invest more than 25% of its assets) in health sciences or related industries, and may invest in companies located in non-U.S. countries.", "manager_name": "Xiang  Liu", "manager_bio": "Ms. Xie is the managing director and Portfolio Manager of BlackRock Advisor since 2006. Before becoming part of BlackRock Advisors in 2005, she was with State Street Research & Management since 2001. Ms. Xie began her investment career as a pharmaceutical analyst for Sanford Bernstein in 1999.", "category": "Health", "family": "BlackRock", "exchange": "NAS", "market": "us_market"}, "SHSCX": {"short_name": "BlackRock HlthSc Op C", "long_name": "BlackRock Health Sciences Opportunities Portfolio Investor C Shares", "currency": "USD", "summary": "The investment seeks to provide long-term growth of capital.\n The fund invests at least 80% of its total assets in equity securities, primarily common stock, of companies in health sciences and related industries. The health sciences sector can include companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals. It will concentrate its investments (i.e., invest more than 25% of its assets) in health sciences or related industries, and may invest in companies located in non-U.S. countries.", "manager_name": "Xiang  Liu", "manager_bio": "Ms. Xie is the managing director and Portfolio Manager of BlackRock Advisor since 2006. Before becoming part of BlackRock Advisors in 2005, she was with State Street Research & Management since 2001. Ms. Xie began her investment career as a pharmaceutical analyst for Sanford Bernstein in 1999.", "category": "Health", "family": "BlackRock", "exchange": "NAS", "market": "us_market"}, "SHSKX": {"short_name": "BlackRock Health Sciences Oppor", "long_name": "BlackRock Health Sciences Opportunities Portfolio Class K", "currency": "USD", "summary": "The investment seeks to provide long-term growth of capital.\n The fund invests at least 80% of its total assets in equity securities, primarily common stock, of companies in health sciences and related industries. The health sciences sector can include companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals. It will concentrate its investments (i.e., invest more than 25% of its assets) in health sciences or related industries, and may invest in companies located in non-U.S. countries.", "manager_name": "Xiang  Liu", "manager_bio": "Ms. Xie is the managing director and Portfolio Manager of BlackRock Advisor since 2006. Before becoming part of BlackRock Advisors in 2005, she was with State Street Research & Management since 2001. Ms. Xie began her investment career as a pharmaceutical analyst for Sanford Bernstein in 1999.", "category": "Health", "family": "BlackRock", "exchange": "NAS", "market": "us_market"}, "SHSSX": {"short_name": "BlackRock HlthSc Op I", "long_name": "BlackRock Health Sciences Opportunities Portfolio Institutional Shares", "currency": "USD", "summary": "The investment seeks to provide long-term growth of capital.\n The fund invests at least 80% of its total assets in equity securities, primarily common stock, of companies in health sciences and related industries. The health sciences sector can include companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals. It will concentrate its investments (i.e., invest more than 25% of its assets) in health sciences or related industries, and may invest in companies located in non-U.S. countries.", "manager_name": "Xiang  Liu", "manager_bio": "Ms. Xie is the managing director and Portfolio Manager of BlackRock Advisor since 2006. Before becoming part of BlackRock Advisors in 2005, she was with State Street Research & Management since 2001. Ms. Xie began her investment career as a pharmaceutical analyst for Sanford Bernstein in 1999.", "category": "Health", "family": "BlackRock", "exchange": "NAS", "market": "us_market"}, "SUHAX": {"short_name": "DWS Health and Wellness Fund - ", "long_name": "DWS Health and Wellness Fund - Class A", "currency": "USD", "summary": "The investment seeks long-term growth of capital.\n Under normal circumstances, the fund will invest at least 80% of net assets, plus the amount of any borrowings for investment purposes, in equity securities of companies in the health care and wellness sectors. It invests primarily in securities of U.S. companies, but may invest in foreign companies as well. The fund may invest in companies of any size. While the fund invests mainly in common stocks, it may also invest up to 20% of total assets in U.S. Treasury and U.S. agency debt obligations.", "manager_name": "Leefin  Lai", "manager_bio": "Lai ,CFA and CPA, is managing director and lead portfolio manager. Joined Deutsche Asset Management in 2001, previously serving as an analyst for Salomon Smith Barney and Paine Webber and as vice president/analyst for Citigroup Global Asset Management and Scudder Kemper Investments. Lai holds the Chartered Financial Analyst designation. Hold a BS and MBA at University of Illinois.", "category": "Health", "family": "DWS", "exchange": "NAS", "market": "us_market"}, "SUHCX": {"short_name": "DWS Health and Wellness Fund - ", "long_name": "DWS Health and Wellness Fund - Class C", "currency": "USD", "summary": "The investment seeks long-term growth of capital.\n Under normal circumstances, the fund will invest at least 80% of net assets, plus the amount of any borrowings for investment purposes, in equity securities of companies in the health care and wellness sectors. It invests primarily in securities of U.S. companies, but may invest in foreign companies as well. The fund may invest in companies of any size. While the fund invests mainly in common stocks, it may also invest up to 20% of total assets in U.S. Treasury and U.S. agency debt obligations.", "manager_name": "Leefin  Lai", "manager_bio": "Lai ,CFA and CPA, is managing director and lead portfolio manager. Joined Deutsche Asset Management in 2001, previously serving as an analyst for Salomon Smith Barney and Paine Webber and as vice president/analyst for Citigroup Global Asset Management and Scudder Kemper Investments. Lai holds the Chartered Financial Analyst designation. Hold a BS and MBA at University of Illinois.", "category": "Health", "family": "DWS", "exchange": "NAS", "market": "us_market"}, "SUHIX": {"short_name": "DWS Health and Wellness Fund - ", "long_name": "DWS Health and Wellness Fund - Class Inst", "currency": "USD", "summary": "The investment seeks long-term growth of capital.\n Under normal circumstances, the fund will invest at least 80% of net assets, plus the amount of any borrowings for investment purposes, in equity securities of companies in the health care and wellness sectors. It invests primarily in securities of U.S. companies, but may invest in foreign companies as well. The fund may invest in companies of any size. While the fund invests mainly in common stocks, it may also invest up to 20% of total assets in U.S. Treasury and U.S. agency debt obligations.", "manager_name": "Leefin  Lai", "manager_bio": "Lai ,CFA and CPA, is managing director and lead portfolio manager. Joined Deutsche Asset Management in 2001, previously serving as an analyst for Salomon Smith Barney and Paine Webber and as vice president/analyst for Citigroup Global Asset Management and Scudder Kemper Investments. Lai holds the Chartered Financial Analyst designation. Hold a BS and MBA at University of Illinois.", "category": "Health", "family": "DWS", "exchange": "NAS", "market": "us_market"}, "SWHFX": {"short_name": "Schwab Health Care Fund", "long_name": "Schwab Health Care Fund", "currency": "USD", "summary": "The investment seeks long-term capital growth.\n To pursue its goal, the fund primarily invests in equity securities issued by companies in the health care sector. The health care sector may include, for example, pharmaceutical and biotechnology companies, health care facilities operations, medical product manufacturers and suppliers, medical providers and medical services firms. It is the fund&#39;s policy that under normal circumstances it will invest at least 80% of its net assets in these securities; typically, the actual percentage will be higher. The fund will concentrate its investments in securities of companies in the health care sector.", "manager_name": "Wei  Li", "manager_bio": "Wei Li, Ph.D., CFA, Senior Portfolio Manager at Charles Schwab Investment Management Inc. Prior to joining CSIM in 2012, Ms. Li spent more than ten years at Barclays Global Investors (now known as BlackRock, Inc.), where she held a number of positions. From 2001 to 2009, she worked in various roles in the Global Advanced Active group, including portfolio management and quantitative research for both U.S. and international equity markets. After 2009, she worked in the defined contribution research and product development area for almost two years.", "category": "Health", "family": "Schwab Funds", "exchange": "NAS", "market": "us_market"}, "THISX": {"short_name": "T. Rowe Price Health Sciences F", "long_name": "T. Rowe Price Health Sciences Fund I Class", "currency": "USD", "summary": "The investment seeks long-term capital appreciation.\n The fund will normally invest at least 80% of its net assets (including any borrowings for investment purposes) in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed \"health sciences\"). While the fund can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-capitalization companies. It is non-diversified.", "manager_name": "Ziad  Bakri", "manager_bio": "Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment ban", "category": "Health", "family": "T. Rowe Price", "exchange": "NAS", "market": "us_market"}, "VCHSX": {"short_name": "VALIC Company I Health Sciences", "long_name": "VALIC Company I Health Sciences Fund", "currency": "USD", "summary": "The investment seeks long-term capital growth.\n The fund normally invests at least 80% of its net assets in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed \"health sciences\"). While the fund can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-cap companies. The fund may invest up to 35% of its total assets in foreign stocks, which include non-dollar denominated securities traded outside the U.S.", "manager_name": "Ziad  Bakri", "manager_bio": "Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment ban", "category": "Health", "family": "VALIC", "exchange": "NAS", "market": "us_market"}, "VGHAX": {"short_name": "Vanguard Health Care Fund Admir", "long_name": "Vanguard Health Care Fund Admiral Shares", "currency": "USD", "summary": "The investment seeks long-term capital appreciation.\n The fund invests at least 80% of its assets in the stocks of companies principally engaged in the development, production, or distribution of products and services related to the health care industry. These companies include, among others, pharmaceutical firms, medical supply companies, and businesses that operate hospitals and other health care facilities. It may also consider companies engaged in medical, diagnostic, biochemical, and other research and development activities. The fund may invest up to 50% of its assets in foreign stocks.", "manager_name": "Jean M. Hynes", "manager_bio": "Jean M. Hynes, CFA, Senior Managing Director and Global Industry Analyst of Wellington Management, has been involved in portfolio management and securities analysis for the health science portion of the Fund since August 2003.\nJean holds a BA in economics from Wellesley College (1991). She joined Wellington Management upon her graduation. She holds the Chartered Financial Analyst designation, and is a member of the CFA Institute and the Boston Security Analysts Society.", "category": "Health", "family": "Vanguard", "exchange": "NAS", "market": "us_market"}, "VGHCX": {"short_name": "Vanguard Specialized Portfolios", "long_name": "Vanguard Health Care Fund Investor Shares", "currency": "USD", "summary": "The investment seeks long-term capital appreciation.\n The fund invests at least 80% of its assets in the stocks of companies principally engaged in the development, production, or distribution of products and services related to the health care industry. These companies include, among others, pharmaceutical firms, medical supply companies, and businesses that operate hospitals and other health care facilities. It may also consider companies engaged in medical, diagnostic, biochemical, and other research and development activities. The fund may invest up to 50% of its assets in foreign stocks.", "manager_name": "Jean M. Hynes", "manager_bio": "Jean M. Hynes, CFA, Senior Managing Director and Global Industry Analyst of Wellington Management, has been involved in portfolio management and securities analysis for the health science portion of the Fund since August 2003.\nJean holds a BA in economics from Wellesley College (1991). She joined Wellington Management upon her graduation. She holds the Chartered Financial Analyst designation, and is a member of the CFA Institute and the Boston Security Analysts Society.", "category": "Health", "family": "Vanguard", "exchange": "NAS", "market": "us_market"}, "VHCIX": {"short_name": "Vanguard HealthCare Index Fund ", "long_name": "Vanguard Health Care Index Fund Admiral Shares", "currency": "USD", "summary": "The investment seeks to track the performance of a benchmark index.\n The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index (IMI)/Health Care 25/50, an index made up of stocks of large, mid-size, and small U.S. companies within the health care sector, as classified under the Global Industry Classification Standard (GICS). The Advisor attempts to replicate the target index by seeking to invest all, or substantially all, of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. The fund is non-diversified.", "manager_name": "Michelle  Louie", "manager_bio": "Michelle Louie, CFA, Portfolio Manager at Vanguard. She has been with Vanguard since 2010, has worked in investment management since 2011. Education: B.S., The American University; M.B.A., Georgia Institute of Technology.", "category": "Health", "family": "Vanguard", "exchange": "NAS", "market": "us_market"}}